A Phase 1 Study of DEC205mAb-NY-ESO-1 Fusion Protein (CDX-1401) Given with Adjuvant PolyICLC in Conjunction with 5-Aza-2'Deoxycytidine (Decitabine) in Patients with MDS or Low Blast Count AML
Description: 

Evaluate the safety of Anti-DEC-205-NY-ESO1 fusion protein given in combination with decitabine 20 mg/m2 intravenously.

Study Number: 

I 227712

Phase: 
I
Principal Investigator: 
ClinicalTrials.Gov ID: 
NCT01834248

To inquire about participating in these studies, call 1-877-ASK-RPCI (1-877-275-7724) or e-mail askrpci@roswellpark.org.